Short Course Hypofractionated Radiotherapy for Frail or Elderly Patients With Meningioma.
elderly
frail
hypofractionated radiotherapy
meningioma
radiation
radiation fractionation
short course
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
13 Jun 2020
13 Jun 2020
Historique:
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
18
7
2020
Statut:
epublish
Résumé
Purpose/Objective(s) The incidence of intracranial meningiomas increases with age. The standard of care treatment is complete surgical excision, followed by radiation therapy (RT) if indicated. However, six weeks of RT can be challenging for elderly or frail patients. The purpose of this study was to determine if short course RT is safe and effective in elderly patients with meningioma. Materials/Methods We performed a retrospective analysis of patients with meningioma treated with short course beam RT (5-15 fractions) at a single institution. Seventeen patients (94%) received 4005 cGy over 15 fractions and one patient (6%) received 2500 cGy over five fractions. Study endpoints were treatment toxicity (edema), progression-free (PFS) and overall survival (OS). Results Eighteen patients with histologically proven (n = 12) or radiologically presumed meningioma (n = 6, presumed grade I) were identified. Median age at treatment was 85 years (66-95 years). There were eight, eight and two patients with grade I, II and III tumours, respectively. Eight patients (44%) had radiologic edema prior to RT. Six (33%) required dexamethasone treatment during RT and the dose was increased during RT for two patients. Fourteen patients had reduced or no edema post-RT and 13 patients had stable or improving symptoms post-RT. Six patients had disease progression (five in-field, one out-of-field). Median PFS was 3.3 and 0.9 years for grade I and II/III tumours, respectively (p = 0.014). Median OS was 3.3 and 2.5 years for grade I and II/III tumours, respectively (p = 0.12). Conclusion Short course RT for elderly patients with meningioma is well-tolerated and can offer disease control for some patients, particularly those with grade I tumours.
Identifiants
pubmed: 32676243
doi: 10.7759/cureus.8604
pmc: PMC7362603
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e8604Informations de copyright
Copyright © 2020, Sarhan et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Med Imaging Radiat Sci. 2015 Jun;46(2):215-222
pubmed: 31052096
J Neurooncol. 2017 Aug;134(1):125-132
pubmed: 28547588
J Neurosurg. 2018 Jul;129(1):35-47
pubmed: 28984517
J Clin Neurosci. 2017 Feb;36:1-5
pubmed: 27815026
Neuro Oncol. 2019 Jan 14;21(Suppl 1):i18-i31
pubmed: 30649489
Chin Clin Oncol. 2017 Jul;6(Suppl 1):S3
pubmed: 28758407
J Neurosurg Sci. 2009 Mar;53(1):7-11
pubmed: 19322130
Neurooncol Pract. 2019 Sep;6(5):346-353
pubmed: 31555449
Strahlenther Onkol. 2015 Dec;191(12):953-60
pubmed: 26490452
J Clin Neurosci. 2015 Sep;22(9):1450-5
pubmed: 26113003
Neuro Oncol. 2020 Feb 20;22(2):278-289
pubmed: 31603516
Surg Neurol. 1987 Apr;27(4):319-22
pubmed: 3824137
J Clin Neurosci. 2008 Aug;15(8):856-62
pubmed: 18554913
Radiat Oncol. 2014 Mar 20;9:78
pubmed: 24650090
Neuro Oncol. 2019 Feb 19;21(3):360-369
pubmed: 30649461
J Clin Oncol. 2004 May 1;22(9):1583-8
pubmed: 15051755
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931